China SXT Pharmaceuticals (SXTC) Non-Current Assets (2018 - 2026)
China SXT Pharmaceuticals (SXTC) posted quarterly Non-Current Assets of $244852.0 for Q1 2026, down 33.29% year-over-year from $367017.0 in Q1 2025, and down 21.24% quarter-over-quarter from $310889.0 in Q3 2025.
China SXT Pharmaceuticals (SXTC) Non-Current Assets (2018 - 2026) Analysis & Trends
China SXT Pharmaceuticals' Non-Current Assets history runs 9 years deep, the most recent figure standing at $244852.0 for Q1 2026.
- In Q1 2026, Non-Current Assets fell 33.29% year-over-year to $244852.0; the TTM figure through Mar 2026 stood at $244852.0 (down 33.29% YoY), while the FY2026 annual figure was $244852.0, down 33.29% from the prior year.
- Non-Current Assets for Q1 2026 stood at $244852.0, down from $310889.0 in the prior quarter.
- The five-year high for Non-Current Assets was $11.1 million in Q1 2022, with the low at $244852.0 in Q1 2026.
- The 5-year median for Non-Current Assets is $8.9 million (2024), against an average of $5.7 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets jumped 724.5% in 2024, then tumbled 96.55% in 2025.
- China SXT Pharmaceuticals' Non-Current Assets stood at $9.8 million in 2022, then sank by 88.87% to $1.1 million in 2023, then surged by 724.5% to $9.0 million in 2024, then sank by 96.55% to $310889.0 in 2025, then decreased by 21.24% to $244852.0 in 2026.
- Business Quant data shows SXTC's Non-Current Assets at $244852.0 in Q1 2026, $310889.0 in Q3 2025, and $367017.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 2.96 Bn |
| 10 | China SXT Pharmaceuticals | 32,029.07 | -28.14 Mn | - | 244,852.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 244,852.00 |
| Sep 30, 2025 | 310,889.00 |
| Mar 31, 2025 | 367,017.00 |
| Sep 30, 2024 | 9.01 Mn |
| Mar 31, 2024 | 8.89 Mn |
| Sep 30, 2023 | 1.09 Mn |
| Mar 31, 2023 | 10.03 Mn |
| Sep 30, 2022 | 9.82 Mn |
| Mar 31, 2022 | 11.09 Mn |
| Sep 30, 2021 | 11.01 Mn |
| Mar 31, 2021 | 11.31 Mn |
| Sep 30, 2020 | 1.98 Mn |
| Mar 31, 2020 | 2.07 Mn |
| Sep 30, 2019 | 5.50 Mn |
| Mar 31, 2019 | 1.88 Mn |
| Sep 30, 2018 | 1.45 Mn |
| Mar 31, 2018 | 1.56 Mn |